You are here

Siteone Therapeutics, Inc.

Company Information
Address
351 Evergreen Dr Ste B-1
Bozeman, MT 59715-2438
United States



Information

UEI: ZKBYHMUQS291

# of Employees: 8


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough

    Amount: $677,568.00

    PROJECT SUMMARYChronic cough, or cough that persists for more than eight weeks, is a condition that is often associated with diseases such as chronic obstructive pulmonary disorder (COPD), asthma, idi ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  2. Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain

    Amount: $1,081,115.00

    PROJECT SUMMARY The absence of safe and effective strategies for the management of ocular pain is motivating the development of a novel topical drug suitable for patient self-administration. Conventio ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  3. Discovery of NaV1.7 Inhibitors for the Treatment of Pain

    Amount: $455,622.00

    PROJECT SUMMARY The objective of our program is to develop a safe and effective nonopioid analgesic for the treatment of neuropathic pain, such as pain associated with chemotherapy-induced peripheral ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  4. Discovery of NaV1.7 Inhibitors for the Treatment of Pain

    Amount: $688,083.00

    PROJECT SUMMARY The objective of our program is to develop a safe and effective nonopioid analgesic for the treatment of neuropathic pain, such as pain associated with chemotherapy-induced peripheral ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  5. Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough

    Amount: $323,733.00

    PROJECT SUMMARYThe objective of our program is to develop a safe and effective therapeutic for chronic coughChronic coughor cough that persists for more than eight weeksis a condition that is often as ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  6. GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN

    Amount: $1,490,020.00

    PROJECT SUMMARY The absence of safe and effective strategies for the management of ocular pain is motivating the development of a novel topical drug suitable for patient self administrationConventiona ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  7. Development of Selective Inhibitors of NaV as Therapeutics for Pain

    Amount: $1,446,169.00

    PROJECT SUMMARY This program aims to develop a novel non opioid therapeutic for the treatment of pain that targets a subtype of the human voltage gated Na ion channel NaV Preliminary data indic ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  8. Guanidinium Derivatives for the Treatment of Ocular Pain

    Amount: $223,828.00

    DESCRIPTION provided by applicant The absence of safe effective strategies for the management of ocular pain is motivating the development of a novel topical drug suitable for patient self adminis ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  9. Molecularly Engineered Biomaterials for Minimally Invasive Dental Treatment

    Amount: $285,048.00

    DESCRIPTION (provided by applicant): Synthetic modification of a natural toxin, gonyautoxin 2/3, is enabling the development of new therapies for painful neuromuscular disorders, such as anal fissure ...

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
  10. Design, Synthesis and Evaluation of Novel Isoform-Selective Sodium Channel Inhibi

    Amount: $236,235.00

    DESCRIPTION (provided by applicant): Side effects associated with opioid analgesics, such as nausea, drowsiness, respiratory depression, and potential for addiction, are motivating the design and dev ...

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government